Nephrotic Syndrome Market Outlook 2026, Global Opportunity & Growth Analysis

Nephrotic syndrome is a kidney disorder defined by collection of symptoms such as proteinuria, hyperlipidemia, hypoalbuminia, edema, and various other complications. It develops following a pathological injury caused to the renal glomeruli, which damages the basement membrane in the renal glomeruli.

Read Report Overview –

The renal glomeruli filter waste and excess water from the blood. Risk factors for nephrotic syndrome may be a primary cause, with the disease being specific to the kidneys. Secondary factors include hepatitis C, diabetes, malaria, systemic lupus, HIV, hepatitis B, congenital infections, or abuse of certain drugs.

Factors driving the global nephrotic syndrome market include increasing incidence and prevalence of nephrotic syndrome worldwide, growing elderly population, high rate of incidence hyperlipidemia, and increasing number of individuals suffering from diabetes. Moreover, other complications such as thromboembolism, HIV, hepatitis B, and hepatitis C also contribute toward the increasing rate of incidence and prevalence of nephrotic syndrome worldwide.

Request Brochure of Report –

The market for nephrotic syndrome is primarily driven by presence of a large patient pool suffering from nephrotic syndrome. According to the WHO, more than 1.4 million people worldwide undergo renal replacement therapy every year, with the rate of incidence of chronic kidney disease (CKD) rising by approximately 8% annually. However, increase in the health care expenditure and stringent regulatory approvals are likely to be restraining factors for the nephrotic syndrome market in the near future.

The global nephrotic syndrome market can be segmented based on drug, and geography. In terms of drug, the market can be classified into sodium restriction drugs, fluid restriction drugs, loop diuretics, angiotensin-converting enzyme inhibitor (or angiotensin receptor blocker therapy), and others. The pipeline of drugs for nephrotic syndrome is relatively small with a total of around 10 products undergoing active development in companies/institutes/universities.

Of the 10 pipeline products, mostly acting on the cause effect of nephrotic syndrome, meaning they act on molecular targets not yet present in any market in the pharmaceutical industry, that are expected to become blockbuster drugs for the indication during the forecast period, generating further market growth within the nephrotic syndrome market.

Request for Custom Research –

Geographically, the global nephropathic syndrome market can be categorized into five key regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held a major share of the global nephrotic syndrome market in 2017. Increase in the prevalence of nephrotic syndrome among infants, rise in funding for research, and growth in awareness about effects of the disease are likely to drive the nephrotic syndrome market in North America during the forecast period. The National Institutes of Health Office of Rare Diseases and the National Institutes of Diabetes, Digestive & Kidney Diseases have renewed the second 5-year funding cycle of the Nephrotic Syndrome Study Network, known as NEPTUNE, by offering a grant of US$ 5.8 Mn to the University of Michigan. The University of Michigan is contributing US$ 4.2 Mn over a 5-year period. Europe and Asia Pacific are projected to gain market share during the forecast period. These regions are likely to account for a significant share of the global market, in terms of revenue, in the near future. Initiatives by local governments to attain self-sufficiency in the production of pharmaceuticals and financial support for research and development of drugs for nephrotic syndrome in countries such as Brazil and South Africa are likely to boost the market in Latin America and Middle East & Africa throughout the forecast period.

Pre Book Nephrotic Syndrome Market Report at

Major players operating in the global nephrotic syndrome market are Asahi Kasei Pharma Corp, Bristol-Myers Squibb Co, Orbis Biosciences Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., Mallinckrodt LLC, Novartis AG and Retrophin, Inc. Companies are adopting organic and inorganic growth strategies to expand their product offerings; enhance their geographical reach; expand their customer base; and gain market share. In 2014, Anthera Pharmaceuticals, Inc. and Zenyaku Kogyo Co., Ltd. entered into an exclusive licensing agreement for development and commercialization of subcutaneous blisibimod in Japan and other countries across Asia.

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.


Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453